Earnings Summary Immunocore Holdings plc IMCR
Intellectia.AI Updated: 1970-01-01
Earnings Summary: Immunocore Holdings plc (IMCR)
Immunocore Holdings plc (IMCR) reported its financial results for the second quarter ending June 30, 2024.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | Year-over-Year Change | Consensus Estimates |
|---|---|---|---|---|
| Total Revenue | $75.3M | $56.9M | +32.3% | $74.58M |
| Earnings Per Share (EPS) | -$0.23 | -$0.20 | -15% | -$0.48 |
Interpretation
Immunocore Holdings exceeded consensus revenue estimates by reporting $75.3 million for Q2 2024, a 32.3% increase from the previous year’s $56.9 million. The company reported an EPS of -$0.23, a better-than-expected result compared to the consensus estimate of -$0.48, though lower than the prior year's Q2 EPS of -$0.20.
Revenue Performance by Segments
| Segment | Q2 2024 Revenue | Previous Guidance |
|---|---|---|
| United States | $55.6M | Not Provided |
| Europe | $15.4M | Not Provided |
| International | $4.3M | Not Provided |
Interpretation
The United States continues to be the primary revenue driver for Immunocore Holdings, contributing $55.6 million in Q2 2024. European revenues amounted to $15.4 million, and international revenue came in at $4.3 million. The company did not provide previous guidance for these regions.
Stock Price Movement
Following the earnings release, Immunocore Holdings's stock price observed a decline of 3.07%.
Note: This summary is based entirely on the data provided in the earnings release content. If some sections are incomplete, it is because there was insufficient data provided in the original input.
